venBio Partners
Venture capitalSan Francisco · Seed–Late Stage · 9 people tracked
Also known as VENBIO PARTNERS LLC
Investment thesis
venBio invests in life sciences companies developing novel therapeutics for unmet medical needs. The firm seeks teams building treatments with meaningful impact on patient care and works closely with them on development strategy, including intellectual property, chemistry and manufacturing (CMC), and clinical trial design and regulatory considerations. venBio is mindful of potential acquisition partners from the outset, positioning its companies to meet acquirer requirements. Its team's expertise and hands-on involvement aim to help companies make a larger impact and build lasting relationships with the leaders it backs.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website & public directories
What they invest in
from 33 of 82 portfolio companiesBiotech ×31Healthtech ×13Medical Devices ×11AI & Machine Learning ×5Deep Tech ×5Digital Health ×2
HQs:United States×32Australia×1
Investments · 82 tracked
founders shown can be your intro pathHarmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)Patrick Morris(Secretary and Treasurer)Jeffrey Aronin(Director)Aaron Royston(Director)Dr. Andreas Wicki(Director)Jack Nielsen(Director)
Board seatAaron Royston· per SEC Form D
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)
Board seatRobert Adelman· per SEC Form D
BiotechVancouver, B.C.
Cindy Jacobs(Executive Officer, Director)Anthony Clarke(Executive Officer)Bridget Martell(Director)Martin Mattingly(Director)Jaime Xinos(Executive Officer)Vaughn Himes(Director)
Aura Biosciences develops targeted oncology therapies based on a virus-like drug conjugate (VDC) technology platform, aimed at cancers with high unmet need.
BiotechMedical DevicesCambridge, US
Raj Parekh, Ph.D.(Director)Michael Wyzga(Executive Officer)Joel Jean-Mairet, Ph.D.(Director)Jose' Baselga, Ph.D.(Director)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)
Cambridge, US
Johnson & Johnson is a diversified healthcare company operating across 260 subsidiary companies with approximately 138,000 employees globally.
BiotechHealthtechMedical DevicesNew Brunswick, US
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)Mark Bachleda(Executive Officer, Director)Robert Vitti(Executive Officer)Dan Estes(Director)Anna Chen(Director)Oliver Stauch(Executive Officer)
HealthtechNew York, US
Steven Elms(Executive Officer, Director, Promoter)Lori Hu(Director)Michael Caldwell(Director)Shawn Leland(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D · $65M raise · filed Nov 2020
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Youssef Bennani(Director)Themasap Khan(Director)Nils Regge(Director)Davis Ryman(Executive Officer)
Board seatRichard Gaster· per SEC Form D
South San Francisco, US
Board seatAaron Royston· per SEC Form D · $45.5M raise · filed Dec 2018
BiotechDublin 2
Corey Goodman(Director)Jaume Pons(Director)Jason Lettman(Director)
Board seatJaume PonsCorey Goodman· per SEC Form D · $36M raise · filed May 2015
Crestwood, US
Board seatRobert Adelman· per SEC Form D · $47.1M raise · filed Feb 2016
Attralus develops a pipeline of novel biologic therapeutics designed to remove toxic amyloid deposits across all stages and types of systemic amyloidosis.
BiotechHealthtechSouth San Francisco, US
Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)Jake Bauer(Director)Spencer Guthrie(Executive Officer)Alex Denner(Director)
Board seatCorey Goodman· per SEC Form D
HealthtechSeattle, US
Michael Hite(Director)John D. Hoekman(Executive Officer, Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $37.3M raise · filed Dec 2016
San Francisco, US
Board seatAaron Royston· per SEC Form D · $160.4M raise · filed Jun 2024
BiotechMenlo Park, US
Albert Cha(Director)Steven L. Basta(Executive Officer, Director)John Creecy(Director)Scott Whitcup(Director)Aaron Royston(Director)Ted Ebel(Director)
Board seatAaron Royston· per SEC Form D · $50.5M raise · filed Jul 2017
BiotechSan Diego, US
Kristina Burow(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)Richard Heyman(Director)Amir Nashat(Director)Robert Adelman(Director)
Board seatRobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Jerel Davis(Director)Ken Song(Executive Officer, Director)Bong Koh(Director)
Board seatAaron Royston· per SEC Form D
BiotechSan Francisco, US
John Borgeson(Mr. Borgeson is the Assistant Secretary of the Issuer.)Robert Adelman(Director)Corey Goodman(Executive Officer, Director, Promoter)Curt Bradshaw(Executive Officer, Director, Promoter)Steven Dowdy(Director)George Rehm(Mr. Rehm is a member of the Board of Managers of the Issuer.)
Board seatRobert Adelman· per SEC Form D · $4M raise · filed Dec 2015
Burlingame, US
Board seatJaume PonsCorey Goodman· per SEC Form D · $61.6M raise · filed Jul 2021
BiotechSan Diego, US
George J. Lee(Director)Jingrong Jean Cui(Executive Officer, Director)Kenneth Fong(Director)Yishan Li(Executive Officer, Director)Bihua Chen(Director)
Board seatRobert Adelman· per SEC Form D · $80M raise · filed Oct 2018
Alexion is a biopharmaceutical company focused on researching and developing treatments for rare diseases, investigating new targets, modalities and technologies to address patient needs globally.
BiotechBoston, US
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
PartnerRobert Adelman· led
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inAmit Mehta(Director)Laura Norris(Executive Officer, Director)Joseph G. Azofeifa(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)
Arrakis Therapeutics discovers and develops RNA-targeted small-molecule drugs, a new drug modality that acts directly on RNA to treat diseases previously inaccessible to genetic medicine.
AI & Machine LearningBiotechDeep TechCambridge, US
Colleen Cuffaro(Director)Michael Gilman(Executive Officer, Director)Carolyn Green(Director)Alan E. Walts(Director)David Neafus(Executive Officer)Raj Parekh(Director)
BiotechSan Francisco, US
Jonathan Silverstein(Director)Steve Squinto(Director)Kush Parmar(Director)Jonathan Leff(Director)Matthew Patterson(Executive Officer, Director)Thomas Woiwode(Director)
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain.
BiotechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Executive Officer, Director)
BoardCorey . Goodman(Director)Jonathan Leff(Director)Raymond J. Kelleher(Director)
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Entact Bio develops ENTAC small-molecule medicines that enhance the function of beneficial proteins by recruiting deubiquitylase (DUB) enzymes, using its Encompass drug-discovery platform to target a range of genetic and complex diseases.
BiotechDeep TechWatertown, US
Ruben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)
BiotechWoburn, US
David Lucchino(Executive Officer, Director)Christopher R. Loose(Executive Officer)Marc Kozin(Director)Robert Langer(Director)Marc Cohen(Director)Timothy Barberich(Director)
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories.
AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US
Ke Cheng(Founder/CEO)inLinh Hoang(Chief Executive Officer)Jerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)Toby Passioura(CSO)Glen McIntyre(COO)COREY GOODMAN(Director)TIMOTHY CRAVEN(Executive Officer, Director)MATT HERSHENSON(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does venBio Partners invest at?
- venBio Partners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does venBio Partners focus on?
- venBio Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is venBio Partners located?
- venBio Partners is headquartered in San Francisco, US.
- Does venBio Partners lead rounds?
- venBio Partners typically participates in rounds rather than leading them.
Co-investors · 35
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
Westlake Village BioPartners is a Los Angeles-based life science venture capital firm that builds and incubates biotech companies around top entrepreneurs, providing hands-on support from ideation through clinical and commercial stages.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
▶23 more co-investors
General CatalystCanaan PartnersPlayground GlobalThird Rock VenturesAbingworthLilly Asia VenturesNew Enterprise Associates (NEA)UberKleiner PerkinsVenrockEclipse VenturesGeneral AtlanticHouseMorgenthalerAccess IndustriesOmega FundsApollo Health VenturesCofounders CapitalSeroba Life Sciences4BIO CapitalRunway Growth CapitalMohr Davidow VenturesLuma Group
Firms observed investing alongside venBio Partners, from public investor directories. Shared companies are the overlap with venBio Partners's recorded portfolio.
Similar investors
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.